Skip to main content
NCBI home page
The Open Ophthalmology Journal logoLink to The Open Ophthalmology Journal
. 2016 May 31;10:146–153. doi: 10.2174/1874364101610010146

Ocular Tolerability of Preservative-Free Tafluprost and Latanoprost: in vitro and in vivo Comparative Study

Yoshihiko Esaki 1, Atsushi Shimazaki 1, Pertti Pellinen 2,*
PMCID: PMC4899509  PMID: 27347250

Abstract

Objective:

Detrimental effects of the preserved prostaglandin analogs (PGAs) have been thoroughly documented in the published literature. The current work studied two preservative-free (PF) prostaglandin eye drops: PF tafluprost and PF latanoprost. The aim of the study was to compare these two PF formulations in vitro for viability of the human corneal epithelial (HCE-T) cells and in vivo for ocular tolerability of the rabbit eye.

Method:

Viability of the HCE-T cells was measured by the MTS assay. The SV40-immortalized HCE-T cells were exposed to 100 µL of the drug solutions (at their commercial concentrations) or the culture medium. Ocular irritation was evaluated after repeated instillation of the drug solutions in Japanese white rabbits (Kbl:JW).

Results:

A significant loss of HCE-T cell viability was observed in vitro immediately after the exposure to PF latanoprost formulation but not immediately after the exposure to PF tafluprost formulation. Congruently, PF latanoprost induced in vivo more irritation on the rabbit eye than PF tafluprost.

Conclusion:

Comparing these two PF formulations in vitro and in vivo, it is considered that ocular tolerability of PF tafluprost is better than PF latanoprost. Taking into account the composition of these two PF PGA formulations, the solubilizing agent macrogolglycerol hydroxystearate 40 (MGHS40) contained in PF latanoprost formulation is a plausible cause for the negative effects.

Keywords: Latanoprost, ocular tolerability, preservative-free, tafluprost

INTRODUCTION

Glaucoma is the leading cause of irreversible visual impairment and blindness worldwide; it is a neuro-degenerative disease that involves the loss of retinal ganglion cells [1]. Elevated intraocular pressure (IOP) is the primary and only mutable risk factor for glaucoma [2]. Thus, topical IOP-lowering medications play a key role in preventing the progression of glaucoma [3]. As these medical therapies usually last for decades, they also need to be essentially safe and well tolerated. Today, prostaglandin analogs (PGAs) are used as the first-line treatment of glaucoma: latanoprost 0.05 mg/mL (Xalatan®, Pfizer, New York USA), travoprost 0.04 mg/mL (Travatan®, Alcon, Fort Worth, USA) and tafluprost 0.015 mg/mL (Taflotan® or Saflutan®, Santen Oy, Tampere, Finland) are all prodrugs of synthetic analogs of prostaglandin F2α (PGF2α) and lower IOP effectively by acting on the prostanoid FP receptors. Bimatoprost 0.1 mg/mL and 0.3 mg/mL (Lumigan®, Allergan, Irvine, USA), in turn, can be regarded as both a prostaglandin prodrug and a prostamide [4-6]. The pharmacological profiles of these compounds have been thoroughly presented and discussed in the published literature [7-10]. All four prostaglandin derivatives lower IOP by 25-35% and cause conjunctival hyperemia and eye irritation with different frequency. The highest rate of hyperemia has been reported for bimatoprost due to an inherent property of the compound [11, 12].

In addition to the direct pharmacological mechanism of action, the formulation of the PGA eye drops may also increase the risk of adverse ocular effects. The PGA molecules are lipophilic by nature and hence challenging to formulate as aqueous solutions. Therefore, excipients need to be added to the solutions that foster solubility and stability of the PGA. Furthermore, a preservative has to be included in all conventional multi-dose containers per se in order to secure sterility and stability of the product [13]. At present, the most commonly used preservative in ophthalmic formulations is benzalkonium chloride (BAC) – a quaternary ammonium salt. In antiglaucoma medications, BAC is typically used with concentrations ranging from 0.04 to 0.25 mg/mL. At these strengths, BAC is toxic in a dose-dependent manner and has deleterious effects on cornea, conjunctiva and trabecular meshwork [13-24]. It also causes and/or exacerbates pre-existing ocular surface disease (OSD) and contributes to the development cataracts in some patients [25-30]. Eventually, BAC may also predispose a patient to a greater risk of trabeculectomy failure [31], a surgical treatment option for the management of glaucoma.

To overcome the adverse effects of BAC, preservative-free (PF) ophthalmic formulations of the PGAs have been developed. Tafluprost 0.015 mg/mL was the first PF eye drop to enter the market [28, 32-34]. Today, also PF latanoprost 0.05 mg/mL (Monoprost®, Thea, Clermont-Ferrand, France) and PF bimatoprost 0.3 mg/mL are commercially available [35, 36]. The formulation of travoprost is still preserved with e.g. polyquaternium-1 (PQ-1), which is known to evoke cytotoxicity and enhance NF-κB-driven inflammation in human corneal epithelial (HCE-2) cells [37-43]. In parallel, however, the excipients targeted to facilitate the solubility and stability of the PF PGA may also induce detrimental effects in the eye. The results of a recent publication affirmed indeed that the solubilizing agent macrogolglycerol hydroxystearate 40 (MGHS40) contained in PF latanoprost formulation was associated with IL-6-mediated inflammatory response and increased cytotoxicity in the HCE-2 cell cultures [44]. No such findings were observed with the formulation of PF tafluprost. The motivation of this paper was to delve further into these two unit-dose PF PGA formulations (i) by evaluating in vitro the effects of PF tafluprost and PF latanoprost on the viability of human corneal epithelial (HCE-T) cells and (ii) by comparing in vivo the ocular tolerability of these PF PGAs [45].

MATERIALS AND METHODOLOGY

Cell Viability Assay

SV40-immortalized HCE-T cells (RIKEN BRC, Japan) were exposed inter alia to 100 µl of the drug solutions (PF tafluprost or PF latanoprost at their commercial concentrations) or the culture medium for the epithelial cells – i.e. DMEM/F-12 (Nacalai Tesque, Japan) supplemented with 10% FFS (Bio West, France) - in a 96-well plate and kept in the CO2 incubator (Panasonic, Japan) at 5% CO2 and 37° C for 5, 15, 30, or 60 minutes.

Viability of the cells was determined by the MTS assay: for each time point, absorbance at the wavelength of 490 nm was measured using the 3550 Microplate Reader BIO-RAD, USA). The final absorbance value was obtained after subtracting the average of blank cells from the measured value. Relative absorbance was calculated as the ratios of drug solutions to the medium (which equals to 100%) at each time point of measurement.

Ocular Irritation Study

Japanese male white rabbits (Kbl:JW) weighing 1.4-2.0 kg were instilled 50 µl of the drug solutions (PF tafluprost or PF latanoprost at their commercial concentrations) on the left eye 10 times a day at 30 minutes intervals; the contralateral eye remained as an untreated control. The study followed a two-period cross-over design: at the initial dosing, the first half of the rabbits (nos. 1-3) received PF latanoprost and the second half (nos. 4-6) PF tafluprost. At the second dosing, after a 6 days washout period, the rabbits switched from PF latanoprost to PF tafluprost and vice versa.

Ocular irritation of the treated eye was determined macroscopically by the McDonald-Shadduck scoring system [46]: conjunctival hyperemia, swelling and discharge were evaluated at 30 minutes, 3 and 5 hours, and 1 day after the last instillation. Cornea, anterior chamber and iris were investigated at the same points of time using a slit lamp. Fluorescein staining of the cornea was evaluated macroscopically at 5 hours after the last instillation and once during the following day. The observer was masked with regard to the identity of the drug solutions.

All the procedures followed were in accordance with the standards set forth in the eight edition of Guide for the Care and Use of Laboratory Animals by the National Academy of Sciences.

Statistical Methods

All results were presented as mean ± standard deviation (SD) unless otherwise indicated. Analysis of variance (ANOVA) model was fitted at each time point for absorbance, and Dunnett’s correction was applied for the pairwise comparisons of drug solutions (PF latanoprost and PF tafluprost) versus the medium. Similarly, two-sample t-test (one-sample t-test) was used to compare the relative absorbance (irritation scores) between the drug solutions. A p-value of less than 0.05 was considered statistically significant.

RESULTS

Cell Viability

The effects of PF tafluprost and PF latanoprost on HCE-T cells - as measured by the MTS assay - are presented in Fig. (1). Overall, cell viability of the culture medium remained stable over the 60 minutes investigational period; the mean absorbance (of four wells) ranged merely from 0.306 ± 0.031 at 5 minutes to 0.367 ± 0.045 at 30 minutes. The wells that were exposed to PF latanoprost, in turn, had the lowest absorbance of 0.262 ± 0.016 already at 5 minutes. After 15 minutes, the absorbance with PF latanoprost started to decline rapidly in a time-dependent manner; that is, from 0.295 ± 0.019 at 15 minutes to 0.110 ± 0.037 at 60 minutes. Hence, statistically significant loss of HCE-T cell viability versus the culture medium was seen at each time point for PF latanoprost. Conversely, such decreases were not seen for PF tafluprost during the first half an hour; the absorbance was 0.297 ± 0.009 at 5 minutes and 0.382 ± 0.030 at 30 minutes. At 60 minutes the viability had diminished in a comparable manner with both PF formulations. Subsequently, the largest differences in relative absorbance between the drug solutions were seen at 15 and 30 minutes (Fig. 1; p < 0.001 for PF tafluprost vs. PF latanoprost at both time points).

Fig. (1).

Fig. (1)

Open in a new tab

The impact of PF tafluprost and PF latanoprost on viability of the HCE-T cells: Relative absorbance by duration of incubation. The bars represent mean ± SEM values; SEM = standard error of the mean; *p<0.05, **p<0.01, ***p<0.001 between the PGA formulations.

Ocular Irritation

Individual and average results of the ocular irritation variables are presented in Table 1 and Fig. (2). Conjunctival hyperemia, swelling and discharge in rabbit eye were all observed with both drug solutions and they appeared to peak at 30 minutes after the last instillation. Each of these three adverse ocular effects was, however, more prominent and severe with PF latanoprost than with PF tafluprost. At 30 minutes, the mean scores of conjunctival hyperemia were still alike (1.67 ± 0.52) for PF tafluprost and PF latanoprost. By 5 hours, conjunctival hyperemia was essentially recovered with PF tafluprost opposite to PF latanoprost for which mild/moderate hyperemia was still widely seen. The mean scores at 5 hours were 0.33 ± 0.52 and 0.83 ± 0.75 (Fig. 2; p < 0.05). At 30 minutes, the mean scores of conjunctival swelling were 0.33 ± 0.52 for both PF treatments. At 3 hours, no swelling was seen with PF tafluprost and one mild case was detected with PF latanoprost. At 30 minutes, the mean scores of conjunctival discharge were 0.50 ± 0.84 for PF tafluprost and 0.67 ± 1.03 for PF latanoprost. One case of mild discharge was still present at 3 hours for both PF treatments. In general, no abnormal findings were seen at the cornea, anterior chamber and iris for either drug formulation with slit lamp examination and fluorescein staining of the cornea.

Table 1.

The results of ophthalmological examinations.

Drug formulation PF latanoprost (Monoprost®) PF tafluprost (Taflotan®)
Irritation variable1 Time point2 1 2 3 4 5 6 mean±SD 1 2 3 4 5 6 mean±SD
  Conjunctival hyperemia 30 minutes 2 2 2 1 1 2 1.67±0.52 1 2 2 2 2 1 1.67±0.52
3 hours 2 2 1 0 1 2 1.33±0.82 1 1 1 1 2 1 1.17±0.41
5 hours 1 2 1 0 0 1 0.83±0.754 0 0 0 0 1 1 0.33±0.52
1 day 0 1 0 0 0 0 0.17±0.41 0 0 0 0 0 0 0.00±0.00
Conjunctival swelling3 30 minutes 1 1 0 0 0 0 0.33±0.52 0 0 1 0 1 0 0.33±0.52
3 hours 1 0 0 0 0 0 0.17±0.41 0 0 0 0 0 0 0.00±0.00
Conjunctival discharge3 30 minutes 2 2 0 0 0 0 0.67±1.03 0 0 0 1 2 0 0.50±0.84
3 hours 1 0 0 0 0 0 0.17±0.41 0 0 0 0 1 0 0.17±0.41
Open in a new tab
1

Each number represents an individual score of ocular irritation by the McDonald-Shadduck scheme: 0=Normal, 1=Slight and 2=Moderate

2

Time after final instillation; left eyes were treated and right eyes were untreated; all scores were zeros for the untreated eyes

3

All scores were zeros at 5 hours and 1 day

4

p<0.05 still with PF latanoprost vs. zero mean (unlike PF tafluprost)

Fig. (2).

Fig. (2)

Open in a new tab

The impact of PF tafluprost and PF latanoprost on conjunctival hyperemia of the rabbits: McDonald-Shadduck irritation scores by duration from last dosing. The bars represent mean ± SEM values; SEM = standard error of the mean; *p<0.05 still with PF latanoprost vs. zero mean (unlike PF tafluprost).

DISCUSSION

The present study compared two distinct PGAs that are available as commercial PF formulations in sterile unit-dose containers; namely, PF tafluprost and PF latanoprost. Other PGAs were not included in the evaluation, since they either had slightly disparate mechanism of action leading by default to a higher risk of ocular irritation (bimatoprost) or were solely available as a preserved formulation in a multi-dose container (travoprost). Specifically, the removal of the preservative from the formulation is of utmost essence, as the most frequently used preservative agents BAC and PQ-1 (a detergent-type derivative from BAC used with travoprost in Europe) have already proven to evoke cytotoxic effects in vitro and induce inflammation on the ocular surface cells [13-24, 37-43]. Therefore, for example, the clinical use of BAC (at 0.04 to 0.25 mg/mL) correlates well with the signs and symptoms of OSD and the failure rate of glaucoma filtration surgery [25-31].

Evidently, the aforementioned harmful effects do not materialize at low strengths of BAC [47]: tafluprost preserved with 0.01 mg/mL of BAC was shown not to be cytotoxic in contrast to travoprost preserved with Sofzia® (an ionic-buffered preservative used in the US) and bimatoprost, travoprost, and latanoprost preserved with 0.05 mg/mL 0.15 mg/mL, and 0.2 mg/mL of BAC, respectively [16, 41]. Sometimes, it has been alleged that these preservatives facilitate the penetration of the PGA into the eye through their detergent activity and hence intensify the efficacy of the drug [48]. However, many studies have now made this past belief close to obsolete and shown that switch to a PF formulation shall, in fact, enhance treatment adherence and efficacy as a result of improved safety and tolerability [28, 32-36]. The PF PGAs have thus directly influenced the clinical guidelines as well as the cost-benefit assessment of the glaucoma treatments [49, 50].

Entirely divergent approaches were undertaken to ensure the solubility of the PGA in PF tafluprost and PF latanoprost formulations: non-ionic surfactants P80 (0.75 mg/mL in PF tafluprost) and MGHS40 (50 mg/mL in PF latanoprost) were utilized as solubilizers, accordingly. The concentration of MGHS40 in PF latanoprost is exceptionally high; it is precisely 1000-fold when compared to that of latanoprost and 250-fold when compared to that of BAC (0.2 mg/mL) in the preserved form of latanoprost. Until recently, information concerning the ocular safety of MGHS40 has been far too scarce - bearing in mind the fact that high concentrations of surface-active compounds are known compromise the integrity of cell membranes [51]. In a seminal paper, finally, the HCE-2 cells were exposed to diluted PF tafluprost, PF latanoprost, BAC, and MGHS40 for 1, 6, 12, 24 and 48 hours, and to undiluted once daily PF tafluprost and PF latanoprost for 9 days [44]. The results of this in vitro study inarguably demonstrated that diluted PF latanoprost, BAC and MGHS40 all exerted concentration and time dependent cellular damage and inflammation, while no relevant morphological changes were displayed by PF tafluprost. Undiluted PF latanoprost also increased significantly the release of LDH and secretion of IL-6 in contrast to undiluted PF tafluprost.

In the present study both in vitro and in vivo methods were used. The cell viability assay clearly demonstrated a difference between the two groups up to 30 minutes of incubation. After one hour the viability decreased significantly in both groups probably reflecting the general study conditions and the sensitivity of the method used. When the hyperemia was assessed no difference between groups could be observed after 30 minutes and 3 hours. This can be explained by the ability of prostaglandin analogs to cause vasodilatation which could initially mask the hyperemia caused by ocular irritation. After 5 hours there was a statistically significant difference between groups indicating irritation induced slower recovery rate of PF latanoprost treated animals.

In essence, the findings of this study provided supplemental in vitro evidence on the detrimental effects of PF latanoprost on the viability of HCE-T cells. Alike, it was further demonstrated that these effects can be seen in vivo when the product is administered topically onto the rabbit eye. On the basis of the earlier results [44] and the fact that other components of the two formulations are well known and widely used in eye drops, the emerged differences between the two PGAs - PF tafluprost and PF latanoprost - can plausibly be attributed to the high concentration of excipient MGHS40.

CONCLUSION

Larger complementary studies are definitively needed to characterize the negative effects of PF latanoprost (and MGHS40) in greater detail. Above all, however, much more attention must be paid to the investigation of the additional excipients included in the ophthalmic formulations – some of them seem to cause similar deleterious effects in vitro and in vivo as the preservatives.

CONFLICT OF INTEREST

The authors confirm that this article content has no conflict of interest.

ACKNOWLEDGEMENTS

The authors would like to thank Dr. Jouni Vuorinen from Oy 4Pharma Ltd for valuable contribution to the preparation of the manuscript.

REFERENCES

  • 1.Kuehn MH, Fingert JH, Kwon YH . Retinal ganglion cell death in glaucoma: mechanisms and neuro-protective strategies. . Ophthalmol Clin N Am . 2005;18:283–395. doi: 10.1016/j.ohc.2005.04.002. [DOI] [PubMed] [Google Scholar]
  • 2.Kass M.A., Heuer D.K., Higginbotham E.J., Johnson C.A., Keltner J.L., Miller J.P., Parrish R.K., II, Wilson M.R., Gordon M.O. The Ocular Hypertension Treatment Study: a randomized trial determines that topical ocular hypotensive medication delays or prevents the onset of primary open-angle glaucoma. Arch. Ophthalmol. 2002;120(6):701–713. doi: 10.1001/archopht.120.6.701. [DOI] [PubMed] [Google Scholar]
  • 3.The AGIS Investigators The Advanced Glaucoma Intervention Study (AGIS): 7. The relationship between control of intraocular pressure and visual field deterioration. Am. J. Ophthalmol. 2000;130(4):429–440. doi: 10.1016/S0002-9394(00)00538-9. [DOI] [PubMed] [Google Scholar]
  • 4.Maxey K.M., Johnson J.L., LaBrecque J. The hydrolysis of bimatoprost in corneal tissue generates a potent prostanoid FP receptor agonist. Surv. Ophthalmol. 2002;47(Suppl. 1):S34–S40. doi: 10.1016/S0039-6257(02)00323-5. [DOI] [PubMed] [Google Scholar]
  • 5.Davies S.S., Ju W.K., Neufeld A.H., Abran D., Chemtob S., Roberts L.J., II Hydrolysis of bimatoprost (Lumigan) to its free acid by ocular tissue in vitro. J. Ocul. Pharmacol. Ther. 2003;19(1):45–54. doi: 10.1089/108076803762718105. [DOI] [PubMed] [Google Scholar]
  • 6.Camras C.B., Toris C.B., Sjöquist B., Milleson M., Thorngren J.O., Hejkal T.W., Patel N., Barnett E.M., Smolyak R., Hasan S.F., Hellman C., Meza J.L., Wax M.B., Stjernschantz J. Detection of the free acid of bimatoprost in aqueous humor samples from human eyes treated with bimatoprost before cataract surgery. Ophthalmology. 2004;111(12):2193–2198. doi: 10.1016/j.ophtha.2004.06.028. [DOI] [PubMed] [Google Scholar]
  • 7.Stjernschantz J.W. From PGF(2α)-isopropyl ester to latanoprost: a review of the development of xalatan: the Proctor Lecture. Invest. Ophthalmol. Vis. Sci. 2001;42(6):1134–1145. [PubMed] [Google Scholar]
  • 8.Hellberg M.R., McLaughlin M.A., Sharif N.A., DeSantis L., Dean T.R., Kyba E.P., Bishop J.E., Klimko P.G., Zinke P.W., Selliah R.D., Barnes G., DeFaller J., Kothe A., Landry T., Sullivan E.K., Andrew R., Davis A.A., Silver L., Bergamini M.V., Robertson S., Weiner A.L., Sallee V.L. Identification and characterization of the ocular hypotensive efficacy of travoprost, a potent and selective FP prostaglandin receptor agonist, and AL-6598, a DP prostaglandin receptor agonist. Surv. Ophthalmol. 2002;47(Suppl. 1):S13–S33. doi: 10.1016/S0039-6257(02)00293-X. [DOI] [PubMed] [Google Scholar]
  • 9.Woodward D.F., Krauss A.H., Chen J., Lai R.K., Spada C.S., Burk R.M., Andrews S.W., Shi L., Liang Y., Kedzie K.M., Chen R., Gil D.W., Kharlamb A., Archeampong A., Ling J., Madhu C., Ni J., Rix P., Usansky J., Usansky H., Weber A., Welty D., Yang W., Tang-Liu D.D., Garst M.E., Brar B., Wheeler L.A., Kaplan L.J. The pharmacology of bimatoprost (Lumigan). Surv. Ophthalmol. 2001;45(Suppl. 4):S337–S345. doi: 10.1016/S0039-6257(01)00224-7. [DOI] [PubMed] [Google Scholar]
  • 10.Takagi Y., Nakajima T., Shimazaki A., Kageyama M., Matsugi T., Matsumura Y., Gabelt B.T., Kaufman P.L., Hara H. Pharmacological characteristics of AFP-168 (tafluprost), a new prostanoid FP receptor agonist, as an ocular hypotensive drug. Exp. Eye Res. 2004;78(4):767–776. doi: 10.1016/j.exer.2003.12.007. [DOI] [PubMed] [Google Scholar]
  • 11.Holló G. The side effects of the prostaglandin analogues. Expert Opin. Drug Saf. 2007;6(1):45–52. doi: 10.1517/14740338.6.1.45. [DOI] [PubMed] [Google Scholar]
  • 12.Sharif N.A., Kelly C.R., Crider J.Y., Williams G.W., Xu S.X. Ocular hypotensive FP prostaglandin (PG) analogs: PG receptor subtype binding affinities and selectivities, and agonist potencies at FP and other PG receptors in cultured cells. J. Ocul. Pharmacol. Ther. 2003;19(6):501–515. doi: 10.1089/108076803322660422. [DOI] [PubMed] [Google Scholar]
  • 13.Baudouin C., Labbé A., Liang H., Pauly A., Brignole-Baudouin F. Preservatives in eyedrops: the good, the bad and the ugly. Prog. Retin. Eye Res. 2010;29(4):312–334. doi: 10.1016/j.preteyeres.2010.03.001. [DOI] [PubMed] [Google Scholar]
  • 14.De Saint Jean M., Brignole F., Bringuier A.F., Bauchet A., Feldmann G., Baudouin C. Effects of benzalkonium chloride on growth and survival of Chang conjunctival cells. Invest. Ophthalmol. Vis. Sci. 1999;40(3):619–630. [PubMed] [Google Scholar]
  • 15.Pisella P.J., Debbasch C., Hamard P., Creuzot-Garcher C., Rat P., Brignole F., Baudouin C. Conjunctival proinflammatory and proapoptotic effects of latanoprost and preserved and unpreserved timolol: an ex vivo and in vitro study. Invest. Ophthalmol. Vis. Sci. 2004;45(5):1360–1368. doi: 10.1167/iovs.03-1067. [DOI] [PubMed] [Google Scholar]
  • 16.Noecker R.J., Herrygers L.A., Anwaruddin R. Corneal and conjunctival changes caused by commonly used glaucoma medications. Cornea. 2004;23(5):490–496. doi: 10.1097/01.ico.0000116526.57227.82. [DOI] [PubMed] [Google Scholar]
  • 17.Kahook M.Y., Noecker R.J. Comparison of corneal and conjunctival changes after dosing of travoprost preserved with sofZia, latanoprost with 0.02% benzalkonium chloride, and preservative-free artificial tears. Cornea. 2008;27(3):339–343. doi: 10.1097/ICO.0b013e31815cf651. [DOI] [PubMed] [Google Scholar]
  • 18.Baudouin C. Detrimental effect of preservatives in eyedrops: implications for the treatment of glaucoma. Acta Ophthalmol. 2008;86(7):716–726. doi: 10.1111/j.1755-3768.2008.01250.x. [DOI] [PubMed] [Google Scholar]
  • 19.Liang H., Baudouin C., Pauly A., Brignole-Baudouin F. Conjunctival and corneal reactions in rabbits following short- and repeated exposure to preservative-free tafluprost, commercially available latanoprost and 0.02% benzalkonium chloride. Br. J. Ophthalmol. 2008;92(9):1275–1282. doi: 10.1136/bjo.2008.138768. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 20.Tressler C.S., Beatty R., Lemp M.A. Preservative use in topical glaucoma medications. Ocul. Surf. 2011;9(3):140–158. doi: 10.1016/S1542-0124(11)70024-6. [DOI] [PubMed] [Google Scholar]
  • 21.Liang H., Pauly A., Riancho L., Baudouin C., Brignole-Baudouin F. Toxicological evaluation of preservative-containing and preservative-free topical prostaglandin analogues on a three-dimensional-reconstituted corneal epithelium system. Br. J. Ophthalmol. 2011;95(6):869–875. doi: 10.1136/bjo.2010.189449. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 22.Pauly A., Roubeix C., Liang H., Brignole-Baudouin F., Baudouin C. In vitro and in vivo comparative toxicological study of a new preservative-free latanoprost formulation. Invest. Ophthalmol. Vis. Sci. 2012;53(13):8172–8180. doi: 10.1167/iovs.12-10766. [DOI] [PubMed] [Google Scholar]
  • 23.Pellinen P., Huhtala A., Tolonen A., Lokkila J., Mäenpä J., Uusitalo H. The cytotoxic effects of preserved and preservative-free prostaglandin analogs on human corneal and conjunctival epithelium in vitro and the distribution of benzalkonium chloride homologs in ocular surface tissues in vivo. Curr. Eye Res. 2012;37(2):145–154. doi: 10.3109/02713683.2011.626909. [DOI] [PubMed] [Google Scholar]
  • 24.Stalmans I., Sunaric Mégevand G., Cordeiro M.F., Hommer A., Rossetti L., Goñi F., Heijl A., Bron A. Preservative-free treatment in glaucoma: who, when, and why. Eur. J. Ophthalmol. 2013;23(4):518–525. doi: 10.5301/ejo.5000270. [DOI] [PubMed] [Google Scholar]
  • 25.Pisella P.J., Pouliquen P., Baudouin C. Prevalence of ocular symptoms and signs with preserved and preservative free glaucoma medication. Br. J. Ophthalmol. 2002;86(4):418–423. doi: 10.1136/bjo.86.4.418. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 26.Jaenen N., Baudouin C., Pouliquen P., Manni G., Figueiredo A., Zeyen T. Ocular symptoms and signs with preserved and preservative-free glaucoma medications. Eur. J. Ophthalmol. 2007;17(3):341–349. doi: 10.1177/112067210701700311. [DOI] [PubMed] [Google Scholar]
  • 27.Leung E.W., Medeiros F.A., Weinreb R.N. Prevalence of ocular surface disease in glaucoma patients. J. Glaucoma. 2008;17(5):350–355. doi: 10.1097/IJG.0b013e31815c5f4f. [DOI] [PubMed] [Google Scholar]
  • 28.Uusitalo H., Chen E., Pfeiffer N., Brignole-Baudouin F., Kaarniranta K., Leino M., Puska P., Palmgren E., Hamacher T., Hofmann G., Petzold G., Richter U., Riedel T., Winter M., Ropo A. Switching from a preserved to a preservative-free prostaglandin preparation in topical glaucoma medication. Acta Ophthalmol. 2010;88(3):329–336. doi: 10.1111/j.1755-3768.2010.01907.x. [DOI] [PubMed] [Google Scholar]
  • 29.Crichton A.C., Vold S., Williams J.M., Hollander D.A. Ocular surface tolerability of prostaglandin analogs and prostamides in patients with glaucoma or ocular hypertension. Adv. Ther. 2013;30(3):260–270. doi: 10.1007/s12325-013-0014-7. [DOI] [PubMed] [Google Scholar]
  • 30.Brandt J.D. Does benzalkonium chloride cause cataract? Arch. Ophthalmol. 2003;121(6):892–893. doi: 10.1001/archopht.121.6.892. [DOI] [PubMed] [Google Scholar]
  • 31.Boimer C., Birt C.M. Preservative exposure and surgical outcomes in glaucoma patients: The PESO study. J. Glaucoma. 2013;22(9):730–735. doi: 10.1097/IJG.0b013e31825af67d. [DOI] [PubMed] [Google Scholar]
  • 32.Uusitalo H., Kaarniranta K., Ropo A. Pharmacokinetics, efficacy and safety profiles of preserved and preservative-free tafluprost in healthy volunteers. Acta Ophthalmol. Suppl. (Oxf.) 2008;242:7–13. doi: 10.1111/j.1755-3768.2008.01380.x. [DOI] [PubMed] [Google Scholar]
  • 33.Hamacher T., Airaksinen J., Saarela V., Liinamaa M.J., Richter U., Ropo A. Efficacy and safety levels of preserved and preservative-free tafluprost are equivalent in patients with glaucoma or ocular hypertension: results from a pharmacodynamics analysis. Acta Ophthalmol. Suppl. (Oxf.) 2008;242:14–19. doi: 10.1111/j.1755-3768.2008.01381.x. [DOI] [PubMed] [Google Scholar]
  • 34.Konstas A.G., Quaranta L., Katsanos A., Riva I., Tsai J.C., Giannopoulos T., Voudouragkaki I.C., Paschalinou E., Floriani I., Haidich A.B. Twenty-four hour efficacy with preservative free tafluprost compared with latanoprost in patients with primary open angle glaucoma or ocular hypertension. Br. J. Ophthalmol. 2013;97(12):1510–1515. doi: 10.1136/bjophthalmol-2012-303026. [DOI] [PubMed] [Google Scholar]
  • 35.Day D.G., Walters T.R., Schwartz G.F., Mundorf T.K., Liu C., Schiffman R.M., Bejanian M. Bimatoprost 0.03% preservative-free ophthalmic solution versus bimatoprost 0.03% ophthalmic solution (Lumigan) for glaucoma or ocular hypertension: a 12-week, randomised, double-masked trial. Br. J. Ophthalmol. 2013;97(8):989–993. doi: 10.1136/bjophthalmol-2012-303040. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 36.Rouland J.F., Traverso C.E., Stalmans I., Fekih L.E., Delval L., Renault D., Baudouin C., T2345 Study Group Efficacy and safety of preservative-free latanoprost eyedrops, compared with BAK-preserved latanoprost in patients with ocular hypertension or glaucoma. Br. J. Ophthalmol. 2013;97(2):196–200. doi: 10.1136/bjophthalmol-2012-302121. [DOI] [PubMed] [Google Scholar]
  • 37.Lewis R.A., Katz G.J., Weiss M.J., Landry T.A., Dickerson J.E., James J.E., Hua S.Y., Sullivan E.K., Montgomery D.B., Wells D.T., Bergamini M.V., Travoprost BAC-free Study Group Travoprost 0.004% with and without benzalkonium chloride: a comparison of safety and efficacy. J. Glaucoma. 2007;16(1):98–103. doi: 10.1097/01.ijg.0000212274.50229.c6. [DOI] [PubMed] [Google Scholar]
  • 38.Choy C.K., Cho P., Boost M.V. Cytotoxicity and effects on metabolism of contact lens care solutions on human corneal epithelium cells. Clin. Exp. Optom. 2012;95(2):198–206. doi: 10.1111/j.1444-0938.2011.00687.x. [DOI] [PubMed] [Google Scholar]
  • 39.Choy C.K., Cho P., Boost M.V., Benzie I.F. Do multipurpose solutions damage porcine corneal epithelial cells? Optom. Vis. Sci. 2009;86(5):E447–E453. doi: 10.1097/OPX.0b013e31819fa422. [DOI] [PubMed] [Google Scholar]
  • 40.Salminen A., Huuskonen J., Ojala J., Kauppinen A., Kaarniranta K., Suuronen T. Activation of innate immunity system during aging: NF-kB signaling is the molecular culprit of inflamm-aging. Ageing Res. Rev. 2008;7(2):83–105. doi: 10.1016/j.arr.2007.09.002. [DOI] [PubMed] [Google Scholar]
  • 41.Ammar D.A., Noecker R.J., Kahook M.Y. Effects of benzalkonium chloride-preserved, polyquad-preserved, and sofZia-preserved topical glaucoma medications on human ocular epithelial cells. Adv. Ther. 2010;27(11):837–845. doi: 10.1007/s12325-010-0070-1. [DOI] [PubMed] [Google Scholar]
  • 42.Paimela T., Ryhänen T., Kauppinen A., Marttila L., Salminen A., Kaarniranta K. The preservative polyquaternium-1 increases cytoxicity and NF-kappaB linked inflammation in human corneal epithelial cells. Mol. Vis. 2012;18:1189–1196. [PMC free article] [PubMed] [Google Scholar]
  • 43.Xu M., Sivak J.G., McCanna D.J. Comparison of the effects of ophthalmic solutions on human corneal epithelial cells using fluorescent dyes. J. Ocul. Pharmacol. Ther. 2013;29(9):794–802. doi: 10.1089/jop.2013.0002. [DOI] [PubMed] [Google Scholar]
  • 44.Smedowski A., Paterno J.J., Toropainen E., Sinha D., Wylegala E., Kaarniranta K. Excipients of preservative-free latanoprost induced inflammatory response and cytotoxicity in immortalized human HCE-2 corneal epithelial cells. J. Biochem. Pharmacol. Res. 2014;2(4):175–184. [PMC free article] [PubMed] [Google Scholar]
  • 45.Pellinen P., Esaki Y., Shimazaki A. Ocular tolerability of preservative-free prostaglandin eye drops. Acta Ophthalmol. Suppl. 2013;91:s252. doi: 10.1111/j.1755-3768.2013.S008.x. [DOI] [Google Scholar]
  • 46.McDonald T. Advances in modern toxicology. Vol. 4. New York: Wiley; 1977. Shadduck J. Eye irritation. p. 162. [Google Scholar]
  • 47.Niwano Y., Iwasawa A., Ayaki M. Ocular surface cytotoxicity and safety evaluation of tafluprost, a recently developed anti-glaucoma prostaglandin analog. Ophthalmol. Eye Dis. 2014;6:5–12. doi: 10.4137/OED.S12445. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 48.Rosin L.M., Bell N.P. Preservative toxicity in glaucoma medication: clinical evaluation of benzalkonium chloride-free 0.5% timolol eye drops. Clin. Ophthalmol. 2013;7:2131–2135. doi: 10.2147/OPTH.S41358. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 49.Ou Y., Goldberg I., Migdal C., Lee P.P. A critical appraisal and comparison of the quality and recommendations of glaucoma clinical practice guidelines. Ophthalmology. 2011;118(6):1017–1023. doi: 10.1016/j.ophtha.2011.03.038. [DOI] [PubMed] [Google Scholar]
  • 50.Denis P. Adverse effects, adherence and cost-benefits in glaucoma treatment. Eur. Ophth. Rev. 2011;5:116–122. doi: 10.17925/EOR.2011.05.02.116. [DOI] [Google Scholar]
  • 51.Parsi K. Interaction of detergent sclerosants with cell membranes. Phlebology. 2015;30(5):306–315. doi: 10.1177/0268355514534648. [DOI] [PubMed] [Google Scholar]

Articles from The Open Ophthalmology Journal are provided here courtesy of Bentham Science Publishers

RESOURCES